Open-label, randomized, parallel-group study of drug–drug interaction of lansoprazole, on quizartinib pharmacokinetics
Latest Information Update: 02 Jun 2020
Price :
$35 *
At a glance
- Drugs Lansoprazole (Primary) ; Quizartinib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 23 May 2020 New trial record